Touchlight, a biotechnology company focused on enzymatic DNA production to enable the genetic medicine revolution, today announces a £42 million fundraising round led by Bridford Investments Limited. The proceeds will allow the Company to more than triple its manufacturing footprint, and increase capacity to up to 1 kilogram of GMP DNA per month once fully operational in Q1 2022. Source: Touchlight Press release 11/3/2021